Artikel
PRISCUS 2.0 – An update and expansion of the first German list of potentially inappropriate medications
Suche in Medline nach
Autoren
-
Nina-Kristin Mann
- Department of Clinical Pharmacology, School of Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany
-
Tim Mathes
- Institute for Research in Operative Medicine, School of Medicine, Faculty of Health, Witten/Herdecke University, Cologne, Germany
-
Andreas Sönnichsen
- Department of General Practice and Family Medicine, Center for Public Health, Medical University of Vienna, Vienna, Austria
-
Katja Niepraschk-von Dollen
- Research Institute of the Local Health Care Funds (WIdO), Berlin, Germany
-
Dawid Pieper
- Institute for Research in Operative Medicine, School of Medicine, Faculty of Health, Witten/Herdecke University, Cologne, Germany
-
Petra A. Thürmann
- Department of Clinical Pharmacology, School of Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany; Philipp Klee-Institute for Clinical Pharmacology, Helios University Hospital Wuppertal, Wuppertal, Germany
| Veröffentlicht: | 19. November 2019 |
|---|
Gliederung
Text
Background: Lists of potentially inappropriate medication (PIM) support clinicians, other healthcare professionals and patients by alerting them to medicines whose risks may outweigh their benefits specifically in older patients. In addition, such lists are used for pharmacoepidemiological research proving the association between use of PIM and adverse outcomes. The PRISCUS list was the first list of potentially inappropriate medication collated specifically for the German market. However, more than 8 years have passed since its publication necessitating an update.
Materials and methods: First, a preliminary list of drugs to be evaluated by experts was generated based on international PIM lists and a literature search. To ensure the relevance of the selected substances for the German healthcare system, we reviewed their prescription prevalence using claims data provided by the AOK Research Institute, the AOK being the largest German statutory health insurance provider. Additionally, claims data reflect changes in preferential prescribing of drug classes (i.e. increasing prescriptions of direct oral anticoagulants). As PIM lists have been criticised for their lack of evidence-based recommendations, we are currently conducting a set of systematic literature searches on adverse events and the safety of different medications in the aged. A group of experts in geriatric medicine (geriatricians, primary care physicians, pharmacists, medical specialists) will rate all selected drugs in a 2-round Delphi process. Preliminary results will be posted on the project’s website to collect further public and expert suggestions. After review and where appropriate inclusion of chosen comments, we will publish a final version of the PRISCUS 2.0 list.
Results: An updated version of the PRISCUS list will be available for health care professionals, researchers, patients and other interested parties.
Conclusion: Like its predecessor, the PRISCUS 2.0 list can be used to improve geriatric pharmacotherapy and will probably be a valuable tool in a variety of research projects.
Funding: BMBF 01KX1812
